

# Ludovic Barault

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/108888/ludovic-barault-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28  
papers

2,214  
citations

18  
h-index

31  
g-index

31  
ext. papers

2,679  
ext. citations

9  
avg, IF

3.94  
L-index

#	Paper	IF	Citations
28	Immunogenic death of colon cancer cells treated with oxaliplatin. <i>Oncogene</i> , <b>2010</b> , 29, 482-91	9.2	693
27	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , <b>2017</b> , 552, 116-120	50.4	290
26	Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. <i>International Journal of Cancer</i> , <b>2008</b> , 122, 2255-9	7.5	237
25	Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. <i>Cancer Research</i> , <b>2008</b> , 68, 8541-6	10.1	234
24	Birthweight, maternal weight trajectories and global DNA methylation of LINE-1 repetitive elements. <i>PLoS ONE</i> , <b>2011</b> , 6, e25254	3.7	119
23	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. <i>Gut</i> , <b>2018</b> , 67, 1995-2005	19.2	119
22	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1994-1999	10.3	93
21	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 963-71	24.4	71
20	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. <i>Cancer Research</i> , <b>2016</b> , 76, 4504-15	10.1	63
19	Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1062-1067	10.3	28
18	DNA methylation of stress-related genes and LINE-1 repetitive elements across the healthy human placenta. <i>Placenta</i> , <b>2012</b> , 33, 183-7	3.4	28
17	The prevalence of loss of imprinting of H19 and IGF2 at birth. <i>FASEB Journal</i> , <b>2013</b> , 27, 3335-43	0.9	28
16	Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 537-47	7.5	23
15	Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 907-920	7.5	23
14	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , <b>2017</b> , 71, 43-50	7.5	22
13	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1800-1806	10.3	22
12	Evolving neoantigen profiles in colorectal cancers with DNA repair defects. <i>Genome Medicine</i> , <b>2019</b> , 11, 42	14.4	19

11	Leukocyte DNA as surrogate for the evaluation of imprinted Loci methylation in mammary tissue DNA. <i>PLoS ONE</i> , <b>2013</b> , 8, e55896	3.7	18
10	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 622	5.3	17
9	A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 91-101.e3	3.8	15
8	BRAF V600E is a determinant of sensitivity to proteasome inhibitors. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 2950-61	6.1	14
7	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. <i>ESMO Open</i> , <b>2019</b> , 4,	6	12
6	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1017-1024	12.9	8
5	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. <i>European Journal of Cancer</i> , <b>2019</b> , 107, 164-174	7.5	6
4	Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
3	Laboratory Methods in Epigenetic Epidemiology <b>2012</b> , 37-56		3
2	True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature. <i>Cancer Letters</i> , <b>2021</b> , 507, 89-96	9.9	3
1	Evolving neoantigen profiles in colorectal cancers with DNA repair defects		1